Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?

Zacks04-11

Though Novavax, Inc. NVAX is one of a handful of vaccine makers that have secured authorizations for its COVID-19 vaccine in the United States, it still struggles to establish a foothold in the target...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2426626576?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/41D0IKqXpOevA73jRCvjig--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2","is_english":true,"pubTime":"2024-04-11 21:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2426626576","market":"us","top_or_hot":-1,"title":"Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?","media":"Zacks","content":"<div>\n<p>Though Novavax, Inc. NVAX is one of a handful of vaccine makers that have secured authorizations for its COVID-19 vaccine in the United States, it still struggles to establish a foothold in the target...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavaxs-nvax-strategic-reshaping-curb-131200793.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Will Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWill Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 21:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novavaxs-nvax-strategic-reshaping-curb-131200793.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Though Novavax, Inc. NVAX is one of a handful of vaccine makers that have secured authorizations for its COVID-19 vaccine in the United States, it still struggles to establish a foothold in the target...</p>\n\n<a href=\"https://finance.yahoo.com/news/novavaxs-nvax-strategic-reshaping-curb-131200793.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/novavaxs-nvax-strategic-reshaping-curb-131200793.html","article_id":"2426626576","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/41D0IKqXpOevA73jRCvjig--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ef34b229359328ddb52bd15cfa3b6b2"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2426626576","pubTimestamp":1712841120,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Though Novavax, Inc. NVAX is one of a handful of vaccine makers that have secured authorizations for its COVID-19 vaccine in the United States, it still struggles to establish a foothold in the target market.This protein-based COVID-19 vaccine is currently the only marketed product in Novavax’s portfolio and utilizes the company’s proprietary nanoparticle technology. NVAX is currently marketing different versions of this vaccine — one in partnership with the Serum Institute of India  under the trade name Covovax and the other produced by Novavax, which is marketed under the trade name Nuvaxovid. In the United States, the vaccine is marketed as Novavax COVID-19 Vaccine, Adjuvanted.At the time when the pandemic was at its peak, Novavax faced manufacturing issues, which delayed its regulatory filing timeline. As a result, the companymissed out on the COVID-19 vaccine windfall, which benefited the mRNA vaccine makers Pfizer PFE/BioNTech BNTX and Moderna MRNA. The mRNA-based vaccines were a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4007":"制药","PFE":"辉瑞","SG9999002232.USD":"Allianz Global High Payout USD","LU0234572021.USD":"高盛美国核心股票组合Acc","NVAX":"诺瓦瓦克斯医药","MRNA":"Moderna, Inc.","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4535":"淡马锡持仓","LU0058720904.USD":"联博国际健康护理基金A","BK4501":"段永平概念","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4551":"寇图资本持仓","BK4532":"文艺复兴科技持仓","BK4592":"伊斯兰概念","BK4581":"高盛持仓","BNTX":"BioNTech SE","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.USD":"United Global Healthcare Acc USD","BK4548":"巴美列捷福持仓","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC"},"translate_title":"Novavax（NVAX）的战略重塑会抑制现金消耗吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"PFE":1,"NVAX":1,"MRNA":1},"content_text":"Though Novavax, Inc. NVAX is one of a handful of vaccine makers that have secured authorizations for its COVID-19 vaccine in the United States, it still struggles to establish a foothold in the target market.\nThis protein-based COVID-19 vaccine is currently the only marketed product in Novavax’s portfolio and utilizes the company’s proprietary nanoparticle technology. NVAX is currently marketing different versions of this vaccine — one in partnership with the Serum Institute of India (Serum) under the trade name Covovax and the other produced by Novavax, which is marketed under the trade name Nuvaxovid. In the United States, the vaccine is marketed as Novavax COVID-19 Vaccine, Adjuvanted.\nAt the time when the pandemic was at its peak, Novavax faced manufacturing issues, which delayed its regulatory filing timeline. As a result, the companymissed out on the COVID-19 vaccine windfall, which benefited the mRNA vaccine makers Pfizer PFE/BioNTech BNTX and Moderna MRNA. The mRNA-based vaccines were also the first ones authorized by the FDA in 2020.\nBy the time Novavax was granted authorization for its vaccine, most of the population had already completed primary vaccination using Pfizer/BioNTech and Moderna’s approved mRNA-based vaccines. The early launch of mRNA-based vaccines helped these vaccine makers establish a firm hold on the market.\nAs the COVID-19 pandemic has ended, the demand for COVID-19 vaccines has dropped. As a result, management started experiencing declining and/or minimal sales from the COVID-19 vaccine. This, in turn, raised uncertainties about generating revenues from COVID-19 vaccine sales. Based on these uncertainties, management expressed concerns about its ability to continue as a going concern beyond February 2025.\nTo rationalize its manufacturing footprint and reduce costs, the company has undertaken multiple restructuring initiatives. These initiatives have not only helped the company in bringing down its current costs but also reduced short-term liabilities by around $800 million last year. In January, management decided to undertake another cost reduction plan, wherein it will reduce its global workforce by 12%.\nThe company is also progressing well with the development of its other vaccine candidates, i.e., stand-alone influenza, COVID-19-influenza combination (CIC) and high-dose COVID vaccines. All of these candidates are currently being evaluated in a phase II study in older adults aged 50 through 80. In May 2023, Novavax reported positive top-line results from this study that showed that all three vaccines were well-tolerated and demonstrated preliminary robust immune responses compared with authorized comparators.\nBased on the above data, management intends to start a pivotal phase III study on the CIC vaccine before this year’s end, with the intent to market the same in 2026 commercially.\nNovavax’s target market is highly competitive. The company faces stiff competition from Pfizer/BioNTech and Moderna not only for the COVID-19 vaccine but also for the pipeline vaccines. These companies are far ahead of Novavax in terms of marketing and distribution of their vaccines and have already catered to billions of people across the globe.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nModerna, Inc. (MRNA) : Free Stock Analysis Report\nNovavax, Inc. (NVAX) : Free Stock Analysis Report\nBioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426626576"}